Results of Operations and Financial Condition. On August 12, 2026, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended June 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Results of Operations and Financial Condition. On May 13, 2026, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Results of Operations and Financial Condition. On March 25, 2026, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the full year ended December 31, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Results of Operations and Financial Condition. On November 12, 2025, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

Entry into a Material Definitive Agreement. On September 25, 2025, Journey Medical Corporation (the “Company”) entered into a Third Amendment to Credit Agreement (the “Third Amendment”), which amends that certain Credit Agreement, dated December 27, 2023 (the “Original Closing Date”), by and among the Company and SWK Funding LLC, and the other the financial institutions party thereto from time to time, as lenders (as amended by that certain First Amendment to Credit Agreement dated July 9, 20…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosures set forth in

Entry into a Material Definitive Agreement. On August 28, 2025, Journey Medical Corporation (the “Company”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”) and Lake Street Capital Markets, LLC (“Lake Street”), as sales agents or principals (each of B. Riley and Lake Street, an “Agent,” and together, the “Agents”), under which the Company may offer and sell, from time to time at its sole discretion, 3,750,000 shares of its…

Termination of a Material Definitive Agreement As previously disclosed, on December 30, 2022 the Company entered into that certain At Market Issuance Sales Agreement (the “Original Sales Agreement”) with B. Riley pursuant to which the Company could offer and sell, from time to time at its sole discretion, 4,900,000 shares of its common stock, through or to B. Riley , in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act. Effective as of August…

Results of Operations and Financial Condition. On August 12, 2025, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended June 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Results of Operations and Financial Condition. On May 14, 2025, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Chief Operating Officer — Ramsey Alloush: Mr. Alloush was promoted to Chief Operating Officer while continuing his role as General Counsel.

Results of Operations and Financial Condition. On March 26, 2025, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the full year ended December 31, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Results of Operations and Financial Condition. On February 5, 2025, Journey Medical Corporation (the “ Journey Medical ”) announced that it expects to report that it had $20.3 million in cash and cash equivalents as of December 31, 2024. Additionally, Journey Medical is reaffirming its previously issued guidance for the full year ended December 31, 2024 of: · $55 to $60 million in net product revenue; · selling, general and administrative expense in the range of $39 to $42 million; and · rese…

Results of Operations and Financial Condition. On November 12, 2024, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

Other Events. On November 4, 2024, Journey Medical announced that the FDA has approved Emrosi TM (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed by Journey Medical in collaboration with DRL. Journey Medical is completing the manufacturing of Emrosi for the U.S. market and anticipates initial supply will be available in late first quarter or early second quarter of…

Results of Operations and Financial Condition. On November 4, 2024, Journey Medical Corporation (“ Journey Medical ” or the “ Company ”) announced preliminary estimated unaudited revenue and selected financial results for the three- and nine-month periods ended September 30, 2024. Journey Medical’s consolidated financial statements for these periods are not yet available. These estimates are based on information currently available to management. Journey Medical’s actual results are not expec…

Results of Operations and Financial Condition. On August 12, 2024, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended June 30, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosures set forth in

Director — Michael C. Pearce: Appointment of Michael C. Pearce as a new director to the Board.

Entry into a Material Definitive Agreement. On July 9, 2024, Journey Medical Corporation (the “ Company ”) entered into an amendment (the “ Amendment ”) to that certain Credit Agreement (as amended by the Amendment, the “ Amended Credit Agreement ”), dated December 27, 2023 (the “ Original Closing Date ”), by and among the Company and SWK Funding LLC, and the other the financial institutions party thereto from time to time, as lenders. The Amendment, among other things, increased the original…

The filing describes material terms of a plan amendment in the proxy statement.

Results of Operations and Financial Condition. On May 13, 2024, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the three months ended March 31, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…

Chief Financial Officer — Joseph Benesch: Mr. Benesch was promoted from interim to permanent Chief Financial Officer.

Results of Operations and Financial Condition. On March 21, 2024, Journey Medical Corporation issued a press release to provide a corporate update and to announce its financial results for the full year ended December 31, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosures set forth in